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Abstract Benign recurrent intrahepatic cholestasis (BRIC)
is an autosomal recessive liver disease characterized by
multiple episodes of cholestasis without progression to
chronic liver disease. The gene was previously assigned
to chromosome 18q21, using a shared segment analysis in
three families from the Netherlands. In the present study
we report the linkage analysis of an expanded sample of
14 BRIC families, using 15 microsatellite markers from
the 18q21 region. Obligate recombinants in two families
place the gene in a 7-cM interval, between markers
D18S69 and D18S64. All intervening markers had sig-
nificant LOD scores in two-point linkage analysis. More-
over, we identified one family in which the BRIC gene
seems to be unlinked to the 18q21 region, or that repre-
sents incomplete penetrance of the BRIC genotype.
Introduction
Benign recurrent intrahepatic cholerstasis (BRIC) is a rare
autosomal recessive liver disease (De Koning et al. 1995)
characterized by intermittent attacks of cholestasis without
extrahepatic bile duct obstruction (Summerskil and Walshe
1959; Brenard et al. 1989). Each cholestatic attack starts
with rising serum bile acid levels, usually followed by hy-
perbilirubinemia and overt cholestasis (Bijleveld et al.
1989; Brenard et al. 1989). The attacks vary in duration
(weeks to months) and resolve spontaneously. No biochem-
ical abnormalities are found in patients between attacks.
The initial episode can occur at any age from infancy to
adulthood, although most patients present before the age
of 25 years. The frequency of attacks varies from several
times a year to less than once per decade (Brenard et al.
1989). Progression to chronic liver disease has not been
observed, but cholestatic episodes result in substantial mor-
bidity, including pronounced weight loss and deficiency
of fat-soluble vitamins. No established treatment is avail-
able, although cholestyramine may alleviate symptoms in
some patients. Development of an effective therapy is
hampered because the basic defect in BRIC is unknown.
The gene for BRIC was originally mapped to chromo-
some 18q21 through the identification of a shared chro-
mosomal segment in three distantly related patients from
an isolated community in the Netherlands (Houwen et al.
1994). The region shared in these patients extended from
D18S363 to D18S55, a genetic distance of more than 20
cM. To facilitate future molecular genetic studies we sub-
sequently started to delimit the region of interest by study-
ing additional BRIC families with a more densly spaced
set of markers. We now present an analysis of 14 BRIC
families from different ethnic sources with microsatellites
selected primarily from the Généthon map, with the addi-
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tion of a few markers from other sources. Based upon this
analysis we have refined the localization of the BRIC lo-
cus to a 7-cM interval between markers D18S69 and
D18S64. We also found that one of the Dutch families
studied showed no linkage to the 18q21 region, indicating
genetic heterogeneity in BRIC.
Subjects and methods
BRIC families
Fourteen families, involving 26 living BRIC patients, were ana-
lyzed. Except for BRIC family 1, which has been reported else-
where (De Koning et al. 1995), the pedigrees of these families are
summarized in Fig.1. Seven of these families have been described
previously as case reports: family 2 (De Pagter et al. 1976), family
6 (Bijleveld et al. 1989), family 7 (Van Berge Henegouwen 1974),
family 8 (Minuk and Shaffer 1987), families B1 and B3 (Rotthauwe
and Rotthauwe 1971) and family B4 (Brenard et al. 1989). The 
diagnosis of BRIC was considered to be established in a patient
whenever two attacks with cholestasis were documented without
any signs of extrahepatic bile duct obstruction with complete reso-
lution of all signs of cholestasis in between attacks.
The parents of the patients in families 4 and B4 were second
cousins, as were the parents of one of the patients in family 5 (Fig.
1). All families studied had Dutch ancestors, except for families
B1 and B3, which are German, and family B4, which is French.
DNA isolation and marker typing
High molecular weight DNA was extracted from whole blood by
the salting-out method as described by Miller et al. (1988). Geno-
typing of the samples was performed using 15 polymorphic mi-
crosatellite markers (Table 1) covering 23 cM of the chromosome
383
Fig. 1 Pedigrees of all benign
recurrrent intrahepatic
cholestasis (BRIC) families in-
cluded in this study, with the
exception of family BRIC-1,
which has been reported by De
Koning et al. (1995). Filled
circles (female) and squares
(male) indicate affected indi-
viduals
Table 1 Characteristics of the
polymorphic markers used in
this study
a 1, Buetow et al. (1994); 
2, Dib et al. (1996); 3, Straub
et al. (1993); 4, Weber (1993)
personal communication
Locus Marker Heterozygosity Size range (nucleotides) Referencea
D18S363 MFD273 0.87 177–247 1, 4
D18S69 AFM248yf1 0.77 194–210 2
D18S39 MFD193 0.77 206–230 1, 3
D18S41 CU18-002 0.72 185–209 1, 3
D18S1152 AFMa054yg5 0.79 256–274 2
D18S1144 AFMa043xg1 0.85 159–181 2
D18S1129 AFMb317zc1 0.84 234–258 2
D18S1103 AFMa239ye9 0.85 240–254 2
D18S1155 AFMa065ye9 0.65 199–209 2
D18S64 AFM212xg5 0.73 188–208 1, 2
D18S38 MFD153 0.66 152–172 3
D18S1147 AFMa049ze5 0.85 204–232 2
D18S60 AFM178xe3 0.36 156–172 2
D18S51 UT574 0.86 267–319 1, 3
D18S55 AFM122XC1 0.76 134–152 2
18q21 region (Fig.2). Markers were derived from the genetic maps
of Généthon (Dib et al. 1996), Straub et al. (1993) and Buetow et
al. (1994). Integration of these maps was performed by using the
published relative position of those markers that appeared in more
than one map (see Table 1). Typically, BRIC families were geno-
typed by polymerase chain reaction (PCR) amplificaton in an LKB
gene ATAQ controller DNA thermal cycler (Pharmacia). The
PCRs were carried out in a total volume of 10 µl containing 80 ng
genomic DNA, 3.2 pmol each primer, 50 mK KCl, 10 mM TRIS-
HCl, pH 8.3, 1.5 mM MgCl2, 200 µM each dATP, dCTP, dGTP
and dTTP, 1.5 mg/ml BSA, 0.15 U Taq DNA polymerase (Perkin
Elmer Cetus). PCR conditions were 1 min 94°C, 30 s 55°C, 30 s
72°C for 30 cycles. The PCR products were analyzed on 6% poly-
acrylamide gels containing 8 M urea. As reference for the allele
sizes, DNAs from CEPH individuals 1331-1, 1331-2 and 1347-2
or a previously typed BRIC patient were included.
Linkage analysis
Pairwise z values between the BRIC locus and each of the markers
were calculated with the MLINK option of LINKAGE version 5.2
(Lathrop et al. 1984). The BRIC locus was modelled as an autoso-
mal recessive, two-allele system with complete penetrance. Based
on a total of 21 patients identified in the Dutch population (ap-
proximately 15 million inhabitants) we used a disease allele fre-
quency of 0.2%. Marker allele frequencies were calculated using
the ILINK option of the LINKAGE package from their occurrence
in the data set. The ILINK option was also used for the calculation
of the maximum lod scores.
Linkage disequilibrium analysis
Linkage disequilibrium (LD) analysis was carried out using a like-
lihood ratio test (Terwilliger 1995). This test assumes that in a
founder population, such as we believe the Dutch samples are de-
rived from, the marker alleles that were present on the ancestral
chromosome in the vicinity of the disease gene will be overrepre-
sented on disease chromosomes, in comparison with normal chro-
mosomes. The test calculates a parameter λ, which is a measure of
this overrepresentation. As it is not known a priori which allele
will be associated with the disease, the likelihoods are calculated
for all alleles for each λ. The likelihoods are then weighed accord-
ing to the population allele frequencies and summed to calculate
the total associated likelihood.
This likelihood ratio test was carried out using only Dutch
BRIC families and the markers D18S39, D18S41, D18S1152,
D18S1144, D18S1129, D18S1155, and D18S1103. These markers
are all located in the interval defined by the absence of recombina-
tions in the families described. For this analysis allele frequencies
were calculated from the Dutch families and rare alleles were
pooled until no allele, or pool of alleles, had a frequency of less
than 4%.
Results
Genotyping of 15 microsatellite markers from the 18q21
region was conducted in 14 BRIC families. Two crossing
over events were detected that define the BRIC critical re-
gion (Fig.3). In family 2 an obligate recombinant between
two affected sibs excluded D18S69 and other proximal
markers. In family 4 the parents of the patient were sec-
ond cousins. However homozygosity is only noted for
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Fig.2 Sex-average map of 15 loci in the BRIC region of chromo-
some 18. Markers and marker order were derived from Buetow et
al. (1994), Dib et al. (1996) and Straub et al. (1993). Genetic dis-
tances (in cM) are indicated
Fig.3 Haplotypes of the sib-
ships of families 2, 4 and 7,
showing the recombinants lo-
calizing the BRIC locus be-
tween D18S69 and D18S64
(families 2 and 4) and display-
ing possible nonlinkage (fam-
ily 7)
markers centromeric to, but not including, D18S64. To-
gether these recombinants reduce the BRIC region to an
interval between D18S64 and D18S69.
Analysis of family 7 revealed that the haplotypes car-
ried by the patient were present in identical form in two
older brothers who had never had any attacks of cholesta-
sis (Fig. 3).
Based upon the genotyping data collected in all 14
BRIC families, pairwise lod scores were calculated as
shown in Table 2. A significant z-value was obtained for
almost all markers studied, with a highest LOD score of
8.638 for D18S1152. In the region defined by the two ob-
ligate recombinants, maximum LOD scores were obtained
at θ = 0.00, except for D18S39. This is due to family 7,
which showed nonlinkage in the model used (i.e. com-
plete penetrance), and happened to be extremely informa-
tive for this marker and less for others (see Fig. 3).
Subsequently, for the seven markers in the region 
defined by the recombinants, i.e., D18S39, D18S41,
D18S1152, D18S1144, D18S1129, D18S1155, and
D18S1103, we investigated whether a nonrandom associa-
tion of alleles at these loci with the BRIC locus could be
found. LD was found only for D18S1129 (λ = 0.406, χ2 =
5.22, 1 df, P = 0.02). Accounting for testing multiple
markers this LD result is suggestive rather than significant.
Discussion
The present study, using 15 markers from the 18q21 re-
gion in 14 BRIC families, confirms the initial assignment
of the BRIC gene to this region. Moreover, identification
of two recombinants considerably reduces the BRIC re-
gion to a 7-cM interval between D18S64 and D18S69.
Genotyping results in the 14 families studied were also
consistent with the marker order derived by the integra-
tion of three different genetic maps. The LD found for
D18S1129 suggests that the BRIC gene resides in the
vicinity of this marker, which will focus the positional
cloning effort for the gene involved.
The present study includes one BRIC family that does
not show linkage to the 18q21 region. The affected indi-
vidual in this family, a classical BRIC patient with the
matching biochemical profile, has two older brothers with
haplotypes identical to the patient, but with a normal
phenotype. The patient, now over 40 years of age, had his
first attack more than 20 years ago, while his older broth-
ers show no signs of the disease. As the age of onset be-
tween all BRIC sib pairs published (Tygstrup 1960; Kühn
1962; Da Silva and De Brito 1966; Biempica et al. 1967;
Rotthauwe and Rotthauwe 1971; Lesser 1973; De Pagter
et al. 1976; Leiber et al. 1979; Bijleveld et al. 1989; Lau
et al. 1989; De Koning et al. 1995) never differed by more
than 10 years, it is unlikely that these older brothers will
have an attack in the future. So, clinically, they are gen-
uinely unaffected. An undetected double recombinant as
an explanation for the identical haplotypes in the patient
and his nonaffected brothers is unlikely, given the very
short intermarker distance in this region. A new mutation
in this particular patient is unlikely too, but cannot be ex-
cluded. Under the assumption of complete penetrance, the
only possible alternative explanation would be the exis-
tence of a second BRIC locus outside the current region of
interest, analogous to a second locus for Progressive Fa-
miliar Intrahepatic Cholestasis (PFIC) recently shown to
exist outside the 18q21 region (Strautnieks et al. 1996).
However PFIC was known to be clinically heterogeneous
to start with (Whittington et al. 1994), while BRIC seems
to be fairly homogeneous, with patients only differing
slightly in the age at onset and the number and severity of
attacks. Thus, athough a second BRIC locus is a straight-
forward explanation of the present results, nonpenetrance
of the disease in the two older brothers also merits con-
sideration as an explanation of the finding of identical
haplotypes in affected and nonaffected individuals in the
same family.
The BRIC gene was initially localized by studying
three distantly related patients (Houwen et al. 1994)
through the identification of a conserved haplotype in all
of these patients. This shared segment approach was
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Table 2 LOD scores for poly-
morphic DNA markers from
the BRIC critical region.
(MLINK/ILINK generated;
families 1a, 1b, 1c, 2, 3, 4, 5,
6, 7, 8, 12, 13, 14, B1, B3, B4)
a Without family 8
Marker θ = 0.000 θ = 0.1 θ = 0.2 θ = 0.3 θ = 0.4 θ = 0.5 Maximum LOD score
D18S363 – ∞ 6.520 4.312 2.292 0.802 0.000 7.592 at θ = 0.028
D18S69 – ∞ 3.572 2.153 1.033 0.325 0.000 4.451 at θ = 0.021
D18S39 – ∞ 5.047 3.430 1.892 0.682 0.000 5.904 at θ = 0.023
D18S41 5.223 3.837 2.459 1.282 0.436 0.000 5.223 at θ = 0.000
D18S1152 8.638 6.153 3.845 1.953 0.654 0.000 8.638 at θ = 0.000
D18S1144 7.806 5.533 3.471 1.803 0.634 0.000 7.806 at θ = 0.000
D18S1129 8.273 5.967 3.779 1.956 0.682 0.000 8.273 at θ = 0.000
D18S1103 6.946 4.921 3.031 1.493 0.470 0.000 6.946 at θ = 0.000
D18S1155 6.231 4.455 2.802 1.428 0.475 0.000 6.231 at θ = 0.000
D18S64 5.958 4.919 3.266 1.778 0.644 0.000 6.042 at θ = 0.011
D18S38 3.666 3.093 1.988 1.033 0.353 0.000 3.782 at θ = 0.016
D18S1147a – ∞ 4.200 2.802 1.491 0.528 0.000 4.754 at θ = 0.035
D18S60 2.241 1.660 1.050 0.526 0.159 0.000 2.241 at θ = 0.000
D18S51a – ∞ 4.661 3.256 1.830 0.680 0.000 5.183 at θ = 0.036
D18S55a – ∞ 2.521 2.094 1.280 0.511 0.000 2.523 at θ = 0.105
based on Lander and Botstein’s (1986) suggestion that a
gene for a specific disease could be mapped by identify-
ing conserved haplotypes in a distantly related population.
It was predicted that this method would require a fairly
dense marker map, because it was envisaged that the pa-
tients to be used in these kind of studies were separated by
many meiotic steps. However, in the study that assigned
the BRIC gene to 18q21 (Houwen et al. 1994), the three
patients studied were only separated by an average of ten
meiotic steps, so only 256 markers were sufficient for the
initial genome screen. This demonstrated that shared seg-
ment mapping can be used to assign a gene by using only
a limited number of markers, whenever a suitable popula-
tion is available. The same principle has been used for the
mapping of other monogenic disorders too, in both hu-
mans (Puffenberger et al. 1994; Carlton et al. 1995;
Kalaydjieva et al. 1996; Newport et al. 1996) and cattle
(Charlier et al. 1996).
Byler disease, a form of PFIC, was mapped to the
BRIC region on chromosome 18q21, by studying two dis-
tantly related patients, both descendants of Jacob Byler
(Carlton et al. 1995). As these two autosomal recessive
cholestatic disorders both map to the same region on chro-
mosome 18, it can hypothesized that they might be caused
by a derangement in the same gene. According to this
model, BRIC could be caused by relatively mild muta-
tions leaving some residual function in the resulting pro-
tein, while Byler disease could be the result of more se-
vere mutations. The clinical and biochemical features of
both diseases suggest that the defect may be found in the
primary bile acid secretory pathway. However, thus far,
no obvious candidate genes have been mapped to this ge-
nomic interval, such as genes belonging to the ABC su-
perfamily known to be involved in many transport
processes in the liver (Allikmets et al. 1996). Therefore,
further fine mapping of the BRIC and Byler loci, and the
assignment of new microsatellite markers to the critical
interval are required to facilitate positional cloning of the
gene(s) involved. To this end a yeast artificial chromo-
some contig spanning the critical region has been con-
structed and will be used as a source for the isolation of
new markers and for the identification of canditate genes.
Additionally, the search for new BRIC families will be
continued to narrow down the region of interest by LD
analysis and/or the identification of informative recombi-
nants. Such families will also be useful to investigate the
possibility of genetic heterogeneity and/or nonpenetrance
in BRIC. The ultimate cloning of the gene(s) involved
will help to determine the relationship between BRIC and
Byler disease, and may provide important insights into the
biology of bile secretion.
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